Published in Clin Exp Metastasis on March 31, 2011
How does cancer cell metabolism affect tumor migration and invasion? Cell Adh Migr (2013) 1.04
Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model. Toxicol Appl Pharmacol (2012) 0.95
An automated cell-counting algorithm for fluorescently-stained cells in migration assays. Biol Proced Online (2011) 0.89
Targeting Histone Deacetylases in Diseases: Where Are We? Antioxid Redox Signal (2014) 0.88
RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis. Cancers (Basel) (2012) 0.87
Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells. J Cell Mol Med (2014) 0.83
Amygdalin influences bladder cancer cell adhesion and invasion in vitro. PLoS One (2014) 0.81
Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells. J Cell Mol Med (2015) 0.79
Valproic acid (VPA) inhibits the epithelial-mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4. J Cancer Res Clin Oncol (2015) 0.79
Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression. Sci Signal (2016) 0.77
Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo. Oncotarget (2015) 0.77
Therapeutic Value of Voltage-Gated Sodium Channel Inhibitors in Breast, Colorectal, and Prostate Cancer: A Systematic Review. Front Pharmacol (2015) 0.77
The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258. Invest New Drugs (2012) 0.77
Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors. Anticancer Drugs (2013) 0.77
Sodium channel-inhibiting drugs and cancer survival: protocol for a cohort study using the CPRD primary care database. BMJ Open (2016) 0.75
Everolimus exhibits anti-tumorigenic activity in obesity-induced ovarian cancer. Oncotarget (2016) 0.75
Anticancer effects of valproic acid on oral squamous cell carcinoma via SUMOylation in vivo and in vitro. Exp Ther Med (2016) 0.75
Tip60 regulates MT1-MMP transcription and invasion of glioblastoma cells through NF-κB pathway. Clin Exp Metastasis (2016) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am (2001) 5.39
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer (2008) 2.67
Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate (2004) 2.49
Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem (2005) 2.06
Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res (2009) 1.68
Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res (2007) 1.66
Focal adhesion disassembly requires clathrin-dependent endocytosis of integrins. FEBS Lett (2009) 1.61
Dietary genistein inhibits metastasis of human prostate cancer in mice. Cancer Res (2008) 1.57
Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate (2006) 1.57
Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol (2005) 1.39
LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells. Oncogene (2009) 1.34
Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res (2008) 1.31
Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res (2006) 1.24
Type I collagen receptor (alpha 2 beta 1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res (2006) 1.24
Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res (2009) 1.19
Different phenotypes in human prostate cancer: alpha6 or alpha3 integrin in cell-extracellular adhesion sites. Neoplasia (2002) 1.13
RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate (2008) 1.09
Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase. Prostate (2007) 1.08
Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate (2007) 1.06
Reorganization of the integrin alpha2 subunit controls cell adhesion and cancer cell invasion in prostate cancer. Int J Oncol (2009) 1.05
Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. Int J Cancer (2008) 1.01
Emerging views of integrin signaling: implications for prostate cancer. J Cell Biochem (2004) 1.01
Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Mol Cancer Ther (2008) 0.99
Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res (2009) 0.99
RGD-containing peptides activate S6K1 through beta3 integrin in adult cardiac muscle cells. J Biol Chem (2003) 0.98
Osteoblasts-derived BMP-2 enhances the motility of prostate cancer cells via activation of integrins. Prostate (2008) 0.98
The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells. Oncogene (2008) 0.94
Alpha9beta1 integrin in melanoma cells can signal different adhesion states for migration and anchorage. Exp Cell Res (2009) 0.93
Inhibitory effect of fucoidan on the adhesion of adenocarcinoma cells to fibronectin. Anticancer Res (2005) 0.90
Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics. BJU Int (2009) 0.90
Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men. BJU Int (2007) 0.87
Altered expression of beta1 integrins in renal carcinoma cell lines exposed to the differentiation inducer valproic acid. Int J Mol Med (2006) 0.83
Beta3 integrins facilitate matrix interactions during transendothelial migration of PC3 prostate tumor cells. Prostate (2005) 0.83
Inhibitory effect of HGF on invasiveness of aggressive MDA-MB231 breast carcinoma cells, and role of HDACs. Br J Cancer (2008) 0.82
Tumor-endothelial cell interactions: therapeutic potential. Microvasc Res (2007) 0.82
Differential expression of integrin subunits in DU-145/AR prostate cancer cells. Oncol Rep (2004) 0.80
Neuroendocrine transdifferentiation induced by VPA is mediated by PPARgamma activation and confers resistance to antiblastic therapy in prostate carcinoma. Prostate (2008) 0.77
Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension. Eur Urol (2010) 1.99
Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res (2006) 1.92
Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy. Eur Urol (2011) 1.62
External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder. Eur Urol (2011) 1.56
CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia (2006) 1.52
Early vs delayed radical cystectomy for 'high-risk' carcinoma not invading bladder muscle: delay of cystectomy reduces cancer-specific survival. BJU Int (2011) 1.50
Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer (2010) 1.42
Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol (2004) 1.41
En bloc stapler ligation of the renal vascular pedicle during laparoscopic nephrectomy. BJU Int (2007) 1.39
Biomarkers of kidney injury. Biomarkers (2011) 1.39
Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia (2008) 1.33
Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression? BJU Int (2008) 1.25
Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sci (2005) 1.20
Expression of Foxp3 in colorectal cancer but not in Treg cells correlates with disease progression in patients with colorectal cancer. PLoS One (2013) 1.13
Molecular heterogeneity of TFE3 activation in renal cell carcinomas. Mod Pathol (2011) 1.11
The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells. Int J Cancer (2008) 1.08
Preoperative staging of renal cell carcinoma with inferior vena cava thrombus using multidetector CT and MRI: prospective study with histopathological correlation. J Comput Assist Tomogr (2005) 1.07
Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors. Cancer Biol Ther (2007) 1.07
Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo. PLoS One (2013) 1.02
MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients. Neoplasia (2013) 1.02
The soluble Decoy Receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma. Mol Cancer (2013) 1.00
The effect of tamsulosin on the resting tone and the contractile behaviour of the female urethra: a functional urodynamic study in healthy women. Eur Urol (2004) 1.00
Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy. Ann Surg Oncol (2011) 1.00
Elective nephron sparing surgery for renal cell carcinoma larger than 4 cm. J Urol (2007) 0.99
Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer. Clin Cancer Res (2009) 0.98
Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001. Life Sci (2010) 0.97
CXCR4 chemokine receptor engagement modifies integrin dependent adhesion of renal carcinoma cells. Exp Cell Res (2007) 0.96
Vaporization of prostates of > or =80 mL using a potassium-titanyl-phosphate laser: midterm-results and comparison with prostates of <80 mL. BJU Int (2008) 0.95
Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC Cancer (2005) 0.95
The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line. Cancer Lett (2011) 0.95
Single center comparison of anastomotic strictures after radical perineal and radical retropubic prostatectomy. Urology (2009) 0.95
Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells. Cancer Lett (2012) 0.95
The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J Cell Mol Med (2008) 0.94
Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells. BMC Cancer (2009) 0.94
α-Catulin downregulates E-cadherin and promotes melanoma progression and invasion. Int J Cancer (2012) 0.92
TNF: a moonlighting protein at the interface between cancer and infection. Front Biosci (2008) 0.91
Single-institution experience with primary tumours of the male urethra. BJU Int (2007) 0.91
Perinephric and renal sinus fat infiltration in pT3a renal cell carcinoma: possible prognostic differences. BJU Int (2008) 0.91
De novo renal cell carcinoma of native and graft kidneys in renal transplant recipients. BJU Int (2010) 0.90
Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction. BJU Int (2007) 0.90
Facilitatory neuromodulative effect of duloxetine on pudendal motor neurons controlling the urethral pressure: a functional urodynamic study in healthy women. Eur Urol (2006) 0.89
Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis. BMC Cancer (2011) 0.89
Prognostic value of melanoma-associated antigen A9 in renal cell carcinoma. Scand J Urol (2012) 0.89
Prognostic variables for shockwave lithotripsy (SWL) treatment success: no impact of body mass index (BMI) using a third generation lithotripter. BJU Int (2011) 0.89
Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a. Urol Oncol (2011) 0.88
Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix. J Cell Mol Med (2009) 0.88
Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). Curr Urol Rep (2014) 0.88
Interleukin-4, interleukin-10, and interleukin-1-receptor antagonist but not transforming growth factor-beta induce ramification and reduce adhesion molecule expression of rat microglial cells. J Neurosci Res (2002) 0.88
HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro. Anticancer Drugs (2011) 0.88
Prognostic stratification of localized renal cell carcinoma by tumor size. J Urol (2008) 0.88
Expression and prognostic relevance of the death receptor CD95 (Fas/APO1) in renal cell carcinomas. Cancer Lett (2010) 0.87
CXC chemokine mRNA expression as a potential diagnostic tool in prostate cancer. Mol Med Rep (2011) 0.87
Ureteric replacement with Meckel's diverticulum. BJU Int (2006) 0.86
Selective transarterial embolization for posttraumatic renal hemorrhage: a second try is worthwhile. J Urol (2011) 0.86
Multicenter evaluation of the prognostic value of pT0 stage after radical cystectomy due to urothelial carcinoma of the bladder. BJU Int (2011) 0.86
Elevation of circulating HLA DR(+) CD8(+) T-cells and correlation with chromium and cobalt concentrations 6 years after metal-on-metal hip arthroplasty. Acta Orthop (2010) 0.85
Predictors for clinically relevant Gleason score upgrade in patients undergoing radical prostatectomy. BJU Int (2011) 0.85
Tumor perfusion assessed by dynamic contrast-enhanced MRI correlates to the grading of renal cell carcinoma: initial results. Eur J Radiol (2009) 0.85
Modified ureterosigmoidostomy (Mainz Pouch II) in different age groups and with different techniques of ureteric implantation. BJU Int (2004) 0.84